Mycoplasma genitalium Infections and Associated Antimicrobial Resistance in Canada, 1980-2023.

IF 2.8 4区医学 Q2 INFECTIOUS DISEASES

Tropical Medicine and Infectious Disease Pub Date : 2025-05-19 DOI:10.3390/tropicalmed10050139

Angela Copete, Mariana Herrera, Camilo Suarez-Ariza, Zipporah Gitau, Maria Arango-Uribe, Rotem Keynan, Camila Oda, Ameeta E Singh, Stuart Skinner, Cara Spence, Will Riaño, Lauren J MacKenzie, Ken Kasper, Laurie Ireland, Irene Martin, Jared Bullard, Lucelly Lopez, Diana Marin, Margaret Haworth-Brockman, Yoav Keynan, Zulma Vanessa Rueda

{"title":"Mycoplasma genitalium Infections and Associated Antimicrobial Resistance in Canada, 1980-2023.","authors":"Angela Copete, Mariana Herrera, Camilo Suarez-Ariza, Zipporah Gitau, Maria Arango-Uribe, Rotem Keynan, Camila Oda, Ameeta E Singh, Stuart Skinner, Cara Spence, Will Riaño, Lauren J MacKenzie, Ken Kasper, Laurie Ireland, Irene Martin, Jared Bullard, Lucelly Lopez, Diana Marin, Margaret Haworth-Brockman, Yoav Keynan, Zulma Vanessa Rueda","doi":"10.3390/tropicalmed10050139","DOIUrl":null,"url":null,"abstract":"Background: We aimed to describe trends in M. genitalium prevalence and associated resistance in Canada between 1980 and 2022.Methods: Ecological study and a scoping review. We collected publicly available data published by the governments of all Canadian provinces and territories. We also systematically searched PubMed, Medline, Embase, and grey literature using the keywords 'M. genitalium', 'Canada', and all provinces and territories. We reported M. genitalium prevalence, age, sex, gender, symptoms, coinfections, sample types used for diagnosis, and macrolide and fluoroquinolone resistance rates.Results: National or provincial surveillance systems for M. genitalium are absent. Eight studies reported the epidemiology of M. genitalium. The prevalence ranged between 3% in Quebec and 30.3% in Ontario. Half of the patients reported symptoms. The most collected sample for M. genitalium diagnosis was urine, followed by cervical and urethral swabs. Co-infection with Chlamydia trachomatis was reported in 3.3% to 16.4% of cases and with Neisseria gonorrhoeae in 0.0% to 24.0%. Macrolide resistance ranged between 25% and 82.1%, and fluoroquinolone resistance between 0.0% and 29.1%.Conclusions: M. genitalium prevalence and resistance rates varied by sex, gender, province, and specimen type. In the absence of routine surveillance, incomplete data hinders understanding the bacterium's natural history, its impact on some key groups, and the tracking of antibiotic resistance.","PeriodicalId":23330,"journal":{"name":"Tropical Medicine and Infectious Disease","volume":"10 5","pages":""},"PeriodicalIF":2.8000,"publicationDate":"2025-05-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12115471/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Tropical Medicine and Infectious Disease","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3390/tropicalmed10050139","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}

引用次数: 0

Abstract

Background: We aimed to describe trends in M. genitalium prevalence and associated resistance in Canada between 1980 and 2022.

Methods: Ecological study and a scoping review. We collected publicly available data published by the governments of all Canadian provinces and territories. We also systematically searched PubMed, Medline, Embase, and grey literature using the keywords 'M. genitalium', 'Canada', and all provinces and territories. We reported M. genitalium prevalence, age, sex, gender, symptoms, coinfections, sample types used for diagnosis, and macrolide and fluoroquinolone resistance rates.

Results: National or provincial surveillance systems for M. genitalium are absent. Eight studies reported the epidemiology of M. genitalium. The prevalence ranged between 3% in Quebec and 30.3% in Ontario. Half of the patients reported symptoms. The most collected sample for M. genitalium diagnosis was urine, followed by cervical and urethral swabs. Co-infection with Chlamydia trachomatis was reported in 3.3% to 16.4% of cases and with Neisseria gonorrhoeae in 0.0% to 24.0%. Macrolide resistance ranged between 25% and 82.1%, and fluoroquinolone resistance between 0.0% and 29.1%.

Conclusions: M. genitalium prevalence and resistance rates varied by sex, gender, province, and specimen type. In the absence of routine surveillance, incomplete data hinders understanding the bacterium's natural history, its impact on some key groups, and the tracking of antibiotic resistance.

查看原文本刊更多论文

1980-2023年加拿大生殖道支原体感染及相关抗菌素耐药性

背景：我们旨在描述1980年至2022年间加拿大生殖器支原体患病率和相关耐药性的趋势。方法：生态学研究和范围综述。我们收集了加拿大所有省份和地区政府公布的公开数据。我们还系统地检索PubMed、Medline、Embase和灰色文献，检索关键词为“M. genitalium”、“Canada”以及所有省份和地区。我们报告了生殖支原体患病率、年龄、性别、症状、合并感染、用于诊断的样本类型以及大环内酯类药物和氟喹诺酮类药物的耐药率。结果：缺乏国家或省级生殖支原体监测系统。八项研究报告了生殖支原体的流行病学。魁北克省的患病率为3%，安大略省为30.3%。一半的患者报告了症状。泌尿生殖道支原体诊断收集最多的样本是尿液，其次是宫颈和尿道拭子。合并感染沙眼衣原体的病例占3.3%至16.4%，合并感染淋病奈瑟菌的病例占0.0%至24.0%。大环内酯类药物耐药率为25% ~ 82.1%，氟喹诺酮类药物耐药率为0.0% ~ 29.1%。结论：生殖道支原体感染率和耐药率因性别、省份和标本类型的不同而不同。在缺乏常规监测的情况下，不完整的数据阻碍了了解细菌的自然史、其对一些关键群体的影响以及抗生素耐药性的跟踪。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊